Sign up
PBYI

Puma Biotechnology Inc (NASDAQ: PBYI)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 0.41%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $6.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 2.3× vs peer median 13.9×

MomentumNeutral

RSI (14) 30.3 (overbought above 70, oversold below 30)

Trend—

—

Short interest10.6% of float

FINRA settlement Oct 30, 2026

PBYI price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

PBYI · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide41Calm Tide—
Squeeze36Watch—
How the scores work →

How PBYI compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Trailing-year return on equity was 22%, higher than 95% of 554 peers.Peer median −68.0% · As of Nov 17, 2026
  2. Trailing-year net margin was 11.6%, higher than 94% of 583 peers.Peer median 0.0% · As of Nov 17, 2026
  3. One-year return was 45.6%, higher than 83% of 522 peers.Peer median −28.4% · As of Nov 17, 2026

Points of caution

  1. One-month return was -32.9%, with only 21% of 567 peers reporting a lower value.Peer median −13.8% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales2.33×13.90×

    Higher than 16% of 407 peers

  • Forward P/E3.46×14.97×

    Not ranked: only 193 of 592 peers report it

  • Price/book3.89×2.57×

    Higher than 64% of 551 peers

Profitability

Profitability metrics are higher than most peers.

  • Gross margin74.8%78.6%

    Not ranked: only 246 of 592 peers report it

  • Operating margin13.4%0.0%
    Top 10% of peers

    Higher than 90% of 442 peers

  • Net margin11.6%0.0%
    Top 10% of peers

    Higher than 94% of 583 peers

  • Return on equity22.0%−68.0%
    Top 10% of peers

    Higher than 95% of 554 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year7.8%0.0%

    Higher than 72% of 592 peers

  • 5-year sales growth rate0.3%11.6%

    Not ranked: only 139 of 592 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio3.035.03

    Higher than 32% of 498 peers

  • Debt/equity (total borrowings)0.000.23

    Not ranked: only 116 of 592 peers report it

Momentum

Returns are higher than most peers.

  • 1-year return+45.6%−28.4%

    Higher than 83% of 522 peers

  • 6-month return+3.3%−26.7%

    Higher than 73% of 545 peers

  • 3-month return−20.7%−29.9%

    Higher than 64% of 558 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
0Buy
1Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$6.00
Average$6.00
High$6.00

As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026$0.06$0.11—
Q2 2026—$0.16—
Q1 2026−$0.13−$0.07—
Annual 2025—$0.61—
Q3 2025—$0.17—
Q2 2025—$0.12—
Q1 2025—$0.06—
Annual 2024$0.14$0.62—

Smart-money activity

In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellMILLER MICHAEL PATRICKSell$121.5KForm 4
Insider sellWILSON TROY EDWARDSell$45.5KForm 4
Insider sellCesano AlessandraSell$567.0KForm 4
Insider sellAUERBACH ALAN HSell$364.1KForm 4
Insider sellHUNT DOUGLAS MSell$69.9KForm 4
Insider sellNOUGUES MAXIMO FSell$77.6KForm 4
Insider sellWILSON TROY EDWARDSell$77.7KForm 4
Insider sellStuglik Brian MSell$58.3KForm 4
Insider sellSenderowicz AdrianSell$194.3KForm 4
Insider sellMOYES JAY MSell$158.8KForm 4
All smart-money activity →

News and press releases

All PBYI news →

Company profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A

CEO
Mr. Alan H. Auerbach
Headquarters
Los Angeles, CA, United States
Employees
179
IPO date
Apr 24, 2012
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.